What is Leap Therapeutics Financial Strength?
Leap Therapeutics has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Leap Therapeutics Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
GuruFocus does not calculate Leap Therapeutics's interest coverage with the available data.
As of today, Leap Therapeutics's Altman Z-Score is 0.00.
Competitive Comparison of Leap Therapeutics's Financial Strength
For the Biotechnology subindustry, Leap Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Leap Therapeutics's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Leap Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Leap Therapeutics's Financial Strength falls into.
Leap Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Leap Therapeutics's Interest Expense for the
months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-14.58 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.15 Mil.
Leap Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is
| GuruFocus does not calculate Leap Therapeutics's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Leap Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
Leap Therapeutics's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Leap Therapeutics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Leap Therapeutics (Leap Therapeutics) Business Description
Traded in Other Exchanges
Address
47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P204,and P205.
Executives
| Jason Baum |
officer: Chief Scientific Officer |
LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141 |
| Patricia A. Martin |
director |
316 BEECHWOOD FARM LANE, INDIANAPOLIS IN 46260 |
| Christian M Richard |
director |
100 FEDERAL STREET, 19TH FLOOR, BOSTON MA 02110 |
| Richard Schilsky |
director |
LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141 |
| Beigene, Ltd. |
10 percent owner |
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108 |
| Christine Granfield |
officer: VP, Head of Reg Affairs/Qual |
C/O LEAP THERAPEUTICS, 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141 |
| Perceptive Life Sciences Master Fund Ltd |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| John Mark O'mahony |
officer: Chief Manufacturing Officer |
C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141 |
| Cynthia Sirard |
officer: Chief Medical Officer |
C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141 |
| Joseph Edelman |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Perceptive Advisors Llc |
10 percent owner |
51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Christopher Mirabelli |
director, 10 percent owner, officer: CEO,Pres,Chairman of the Board |
55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142 |
| Augustine Lawlor |
10 percent owner, officer: Chief Operating Officer |
55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142 |
| Douglas E Onsi |
10 percent owner, officer: CFO,Gen Counsel,Treas, Sec. |
C/O TOLERRX INC, 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Healthcare Ventures Ix, L.p. |
10 percent owner |
55 CAMBRIDGE PARKWAY, SUITE 102, CAMBRIDGE MA 02142 |
Leap Therapeutics (Leap Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LPTX has been successfully added to your